Association Between Fat-soluble Vitamins and Lipid Profile in the Overweight Population

Page: [56 - 62] Pages: 7

  • * (Excluding Mailing and Handling)

Abstract

Background & Aims: It is well-known that the coronary artery stenosis is related to lipid profile. This is a descriptive cross-sectional study to investigate the relationship between the serum fat-soluble vitamins (A, E and D), circulating proprotein convertase subtilisin/kexin type 9 (PCSK9), and lipid profile in the study population.

Methods: A total of 120 overweight subjects were participated in this study. The circulating PCSK9 and vitamin D were measured by ELISA technique. The serum vitamin A and vitamin E amounts were simultaneously measured by the HPLC method. The Serum Small Dense LDLCholesterol (sdLDL-C) values were evaluated using heparin-Mg2+ precipitation technique. The lipid profile was measured by routine laboratory techniques.

Results: The serum vitamin E values correlated significantly to vitamin A (r= 0.47, P= 0.0001), VLDL-C (r= 0.30, P= 0.002), total cholesterol (r= 0.309, P= 0.001), PCSK9 (r= 0.233, P= 0.01) and total triglyceride (r= 0.61, P= 0.0001) values. The circulating PCSK9 values correlated significantly to LDL-C (r= 0.17, P= 0.05) and total cholesterol (r= 0.23, P= 0.009) values. However, there were not correlations between the levels of serum D and A vitamins, the serum LDL-C, sdLDL-C and total cholesterol values.

Conclusion: The data showed the correlations between serum vitamin E and PCSK9-related LDLC values lower than the normal range. Furthermore, the results suggested a nutritional need on the patents considering supplementation or fortification of vitamin E for the overweight subjects with higher LDL-C levels.

Keywords: Vitamin E, vitamin D, vitamin A, sdLDL-C, LDL-C, PCSK9, overweight population.

Graphical Abstract

[1]
Minematsu K, Bang O, Uehara T. Risk factorsIntracranial Atherosclerosis. 1st ed. Chichester: Wiley-Blackwell 2008; pp. 45-54.
[2]
Zhang PY, Xu X, Li XC. Cardiovascular diseases: oxidative damage and antioxidant protection. Eur Rev Med Pharmacol Sci 2014; 18(20): 3091-6.
[PMID: 25392110]
[3]
Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation 1997; 95(1): 69-75.
[http://dx.doi.org/10.1161/01.CIR.95.1.69] [PMID: 8994419]
[4]
Hoogeveen RC, Gaubatz JW, Sun W, Dodge RC, Crosby JR, Jiang J, et al. Small Dense LDL Cholesterol Concentrations Predict Risk for Coronary Heart Disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 2014; 34(5): 1069.
[http://dx.doi.org/10.1161/ATVBAHA.114.303284] [PMID: 24558110]
[5]
Björnheden T, Babyi A, Bondjers G, Wiklund O. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 1996; 123(1-2): 43-56.
[http://dx.doi.org/10.1016/0021-9150(95)05770-6] [PMID: 8782836]
[6]
Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM 2006; 99(1): 1-14.
[http://dx.doi.org/10.1093/qjmed/hci154] [PMID: 16371404]
[7]
Kim DE, Kim JY, Jeong SW, et al. Association between changes in lipid profiles and progression of symptomatic intracranial atherosclerotic stenosis: a prospective multicenter study. Stroke 2012; 43(7): 1824-30.
[http://dx.doi.org/10.1161/STROKEAHA.112.653659] [PMID: 22539545]
[8]
Tsugawa N. Cardiovascular Diseases and Fat Soluble Vitamins: Vitamin D and Vitamin K. J Nutr Sci Vitaminol (Tokyo) 2015; 61(Suppl.): S170-2.
[http://dx.doi.org/10.3177/jnsv.61.S170] [PMID: 26598844]
[9]
Vardi M, Levy NS, Levy AP. Vitamin E in the prevention of cardiovascular disease: the importance of proper patient selection. J Lipid Res 2013; 54(9): 2307-14.
[http://dx.doi.org/10.1194/jlr.R026641] [PMID: 23505320]
[10]
Meydani M. Vitamin E and atherosclerosis: beyond prevention of LDL oxidation. J Nutr 2001; 131(2): 366S-8S.
[http://dx.doi.org/10.1093/jn/131.2.366S] [PMID: 11160562]
[11]
Takeda M, Yamashita T, Sasaki N, et al. Oral administration of an active form of vitamin D3 (calcitriol) decreases atherosclerosis in mice by inducing regulatory T cells and immature dendritic cells with tolerogenic functions. Arterioscler Thromb Vasc Biol 2010; 30(12): 2495-503.
[http://dx.doi.org/10.1161/ATVBAHA.110.215459] [PMID: 20930170]
[12]
Khaw KT, Luben R, Wareham N. Serum 25-hydroxyvitamin D, mortality, and incident cardiovascular disease, respiratory disease, cancers, and fractures: a 13-y prospective population study. Am J Clin Nutr 2014; 100(5): 1361-70.
[http://dx.doi.org/10.3945/ajcn.114.086413] [PMID: 25332334]
[13]
Jamali N, Sorenson CM, Sheibani N. Vitamin D and regulation of vascular cell function. Am J Physiol Heart Circ Physiol 2018; 314(4): H753-65.
[http://dx.doi.org/10.1152/ajpheart.00319.2017] [PMID: 29351464]
[14]
Kassi E, Adamopoulos C, Basdra EK, Papavassiliou AG. Role of vitamin D in atherosclerosis. Circulation 2013; 128(23): 2517-31.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.002654] [PMID: 24297817]
[15]
Farhangi MA, Keshavarz SA, Eshraghian M, Ostadrahimi A, Saboor-Yaraghi AA. Vitamin A supplementation, serum lipids, liver enzymes and C-reactive protein concentrations in obese women of reproductive age. Ann Clin Biochem 2013; 50(Pt 1): 25-30.
[http://dx.doi.org/10.1258/acb.2012.012096] [PMID: 23148279]
[16]
Bennett AL, Lavie CJ. Vitamin D Metabolism and the Implications for Atherosclerosis. Adv Exp Med Biol 2017; 996: 185-92.
[http://dx.doi.org/10.1007/978-3-319-56017-5_15] [PMID: 29124700]
[17]
Patel JV, Caslake MJ, Vyas A, et al. Triglycerides and small dense low density lipoprotein in the discrimination of coronary heart disease risk in South Asian populations. Atherosclerosis 2010; 209 ot(2): 579-84.
[http://dx.doi.org/10.1016/j.atherosclerosis.2009.10.010] [PMID: 19922937]
[18]
Schaefer EJ, McNamara J. Overview of the diagnosis and treatment of lipid disordersHandbook of lipoprotein testing. Washington: AACC press 1997; pp. 25-48.
[19]
Rifai N, Bachorik PS, Albers JJ. Lipids, lipoproteins and apolipoproteinsTietz Textbook of Clinical Chemistry. 3rd ed. Philadelphia: W.B Saunders Company 1999; pp. 809-61.
[20]
Nauck M, Warnick GR, Rifai N. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem 2002; 48(2): 236-54.
[PMID: 11805004]
[21]
Soltanmohammadi E, Piran S, Mohammadi A, et al. Serum sdLDL-C and Cellular SREBP2-dependent Cholesterol Levels; is there a Challenge on Targeting PCSK9? J Med Biochem 2016; 35(4): 410-5.
[http://dx.doi.org/10.1515/jomb-2016-0019] [PMID: 28670193]
[22]
Yazdi SA, Yazdinejad RS. Simultaneous Determination of Vitamin A and E in Infant Milk Formulas Using Semi-Micro liquid–liquid Extraction Followed by HPLC-UV. J Liq Chromatogr Relat Technol 2014; 37: 391-403.
[http://dx.doi.org/10.1080/10826076.2012.745143]
[23]
Tarchalski J, Guzik P, Wysocki H. Correlation between the extent of coronary atherosclerosis and lipid profile. Mol Cell Biochem 2003; 246(1-2): 25-30.
[http://dx.doi.org/10.1023/A:1023443609730] [PMID: 12841339]
[24]
Tribble DL, Rizzo M, Chait A, Lewis DM, Blanche PJ, Krauss RM. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am J Med 2001; 110(2): 103-10.
[http://dx.doi.org/10.1016/S0002-9343(00)00700-2] [PMID: 11165551]
[25]
Xu RX, Li S, Zhang Y, et al. Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease. Lipids Health Dis 2014; 13(1): 188.
[http://dx.doi.org/10.1186/1476-511X-13-188] [PMID: 25496400]
[26]
Bita Hosseni B, Shabani M, Mohammadi A, Naseri F, Soltanmohammadi E, Piran P, et al. Plasma PCSK9 level affects passively LAMP-2 expression; an evidence of transcription network. Gene Rep 2016; 4: 258-63.
[http://dx.doi.org/10.1016/j.genrep.2016.07.005]
[27]
Naseri F, Mohammadi A, Hosseni B, Shabani M. PCSK9-related LDL-C value is correlated to Rab5 isoform expression level. Gene Rep 2017; 6: 128-31.
[http://dx.doi.org/10.1016/j.genrep.2016.12.012]
[28]
Gouni-Berthold I. PCSK9 antibodies: A new class of lipid-lowering drugs. Atheroscler Suppl 2015; 18: 21-7.
[http://dx.doi.org/10.1016/j.atherosclerosissup.2015.02.003] [PMID: 25936300]
[29]
Devaraj S, Tang R, Adams-Huet B, et al. Effect of high-dose α-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease. Am J Clin Nutr 2007; 86(5): 1392-8.
[http://dx.doi.org/10.1093/ajcn/86.5.1392] [PMID: 17991651]
[30]
Romanus EO, Matthew EA. Effect of Oral Vitamin E on Serum Lipid Profile of Apparently Healthy Nigerians in Benin City. Trop J Pharm Res 2015; 14(6): 1071.
[http://dx.doi.org/10.4314/tjpr.v14i6.19]
[31]
Galli F, Varga Z, Balla J, et al. Vitamin E, lipid profile, and peroxidation in hemodialysis patients. Kidney Int Suppl 2001; 78: S148-54.
[http://dx.doi.org/10.1046/j.1523-1755.2001.59780148.x] [PMID: 11169001]
[32]
Jialal I, Fuller CJ, Huet BA. The effect of α-tocopherol supplementation on LDL oxidation. A dose-response study. Arterioscler Thromb Vasc Biol 1995; 15(2): 190-8.
[http://dx.doi.org/10.1161/01.ATV.15.2.190] [PMID: 7749825]
[33]
Perugini C, Bagnati M, Cau C, et al. Distribution of lipid-soluble antioxidants in lipoproteins from healthy subjects. I. Correlation with plasma antioxidant levels and composition of lipoproteins. Pharmacol Res 2000; 41(1): 55-65.
[http://dx.doi.org/10.1006/phrs.1999.0552] [PMID: 10600270]
[34]
Olsen T, Vinknes KJ, Svingen GFT, et al. Cardiovascular disease risk associated with serum apolipoprotein B is modified by serum vitamin A. Atherosclerosis 2017; 265: 325-30.
[http://dx.doi.org/10.1016/j.atherosclerosis.2017.07.020] [PMID: 28774484]
[35]
Wang H, Xia N, Yang Y, Peng DQ. Influence of vitamin D supplementation on plasma lipid profiles: a meta-analysis of randomized controlled trials. Lipids Health Dis 2012; 11: 42.
[http://dx.doi.org/10.1186/1476-511X-11-42] [PMID: 22433171]